United States Patent 10,111,840 (CBD, Dravet/Lennox-Gastaut, ≥98% purity, ≤0.15% Δ9-THC, ~20 mg/kg/day): Scope, Claim Map, and US Patent Landscape
US Patent 10,111,840 claims a narrow, regimen-style method for treating atonic seizures associated with Dravet syndrome or Lennox-Gastaut syndrome using cannabidiol (CBD) with tightly constrained composition/purity/THC parameters and a specific daily dose, with dependent claim coverage for specific co-administration patterns and a defined liquid composition vehicle (sweetener, flavor, solvent/cosolvent, and concentration ranges). The patent’s commercial leverage is concentrated around CBD products intended to track the claimed purity specification (≥98% CBD, ≤0.15% Δ9-THC) and the ~20 mg/kg/day regimen, plus a sub-scope for formulated oral solutions in the cited vehicle/concentration band.
What does US Patent 10,111,840 claim, and what is its technical scope?
Short answer: It claims a method-of-treatment for atonic seizures in Dravet or Lennox-Gastaut using CBD under strict quality parameters (purity and Δ9-THC limit) at an approximately fixed dose (~20 mg/kg/day), with additional dependent claims covering (i) monotherapy vs. adjunct use patterns (dose reduction of concomitant AEDs) and (ii) a specific oral formulation composition (solvent/cosolvent/sweetener/flavor) and concentration ranges.
Independent claim 1: the core infringement hook
Claim 1 recites:
- Patient condition: “atonic seizures” in patients with Dravet syndrome or Lennox-Gastaut syndrome
- Therapeutic agent: cannabidiol (CBD)
- CBD purity/THC limits
- CBD purity ≥ 98% (w/w)
- Δ9-THC ≤ 0.15% (w/w)
- Dose: “about 20 mg/kg/day”
Scope implications
- The claim is not a “CBD for epilepsy” broad brush. It is anchored to:
- seizure type (“atonic seizures”), and
- syndromic population (Dravet or Lennox-Gastaut), and
- CBD quality specification (purity and Δ9-THC threshold), and
- dose near 20 mg/kg/day.
This is an unusually tight combination, making non-infringing design-arounds most likely by shifting at least one axis: dose, THC/purity, seizure targeting in label/practice, or the exact therapeutic regimen.
How strong is the claim construction for purity (≥98% CBD; ≤0.15% Δ9-THC) and “about 20 mg/kg/day”?
Purity and THC specification: what must be proven
For method claims, infringement typically turns on whether the accused product, as administered, meets the claimed parameters. Here, the parameters are:
- CBD purity at least 98% (w/w)
- Δ9-tetrahydrocannabinol at most 0.15% (w/w)
Claim strength drivers
- If the accused product’s COA (certificate of analysis) routinely shows CBD at/above 98% and Δ9-THC at/under 0.15% by weight, the purity axis becomes highly evidence-driven and can be litigated via batch records and COAs.
- If the accused product has a materially different purity spec (including “0.3% THC” grade products, broader THC bands, or different purification strategy), the patent’s purity limitations become a direct defense lever.
“About 20 mg/kg/day”: flexibility vs. boundary
“About” creates a tolerance zone, but the claim still targets an approximate daily dosing regimen.
Practical infringement risk
- For a product and protocol that is consistently titrated to a daily dose close to 20 mg/kg/day, risk is higher.
- For regimens that are deliberately run lower (for example, 10 mg/kg/day or 12.5 mg/kg/day) or higher by a meaningful margin, the “about” language can be contested. The burden is then to show whether the practiced dose is still “about” 20 mg/kg/day as construed in litigation.
What dependent claims add to the infringement scope (Dravet vs LGS; adjunct AED use; dose reduction of concomitant AEDs)?
Claims 2 and 3: syndrome narrowing
- Claim 2: method of claim 1 where the patient has Dravet syndrome
- Claim 3: method of claim 1 where the patient has Lennox-Gastaut syndrome
These dependents narrow the claimed population but do not add new technical constraints. If claim 1 is met, syndrome-specific labeling and patient selection can still matter for proof.
Claims 4–7: combination with AEDs and the “reduction” theory
- Claim 4: CBD administered in combination with one or more concomitant AEDs at recommended therapeutic dose
- Claim 5: AED selection is limited to a list:
clobazam; clonazepam; levetiracetam; topiramate; stiripentol; phenobarbital; lacosamide; valproic acid; zonisamide; perampanel; fosphenytoin
- Claim 6: the number of different anti-epileptic drugs is reduced
- Claim 7: the recommended therapeutic dose of the one or more AEDs is reduced from the recommended therapeutic dose without CBD
Scope implications
- Claims 4–5 target the common real-world use case of CBD as adjunct therapy.
- Claims 6–7 are more demanding: they require that CBD use results in:
- a reduction in the number of AEDs administered, and/or
- a reduction in the AED dose versus a baseline “without CBD” recommended therapeutic dose.
Enforcement note
- These dependent claims tend to create litigation complexity because they hinge on comparative baseline dosing and treatment adjustment rationale, plus evidence of clinical management decisions consistent with “reduced” and “without CBD” benchmarks.
What formulations are protected by US Patent 10,111,840 (solvent/cosolvent/sweetener/flavor/concentration bands)?
Claims 8–14: composition-as-used for the method
Claims 8–14 attach a defined oral composition to the method:
- Claim 8: composition comprising CBD + solvent + co-solvent + sweetener + flavoring
- Claim 9: solvent is sesame oil
- Claim 10: co-solvent is ethanol
- Claim 11: sweetener is sucralose
- Claim 12: flavoring is strawberry flavor
- Claim 13: CBD concentration 25 mg/ml to 100 mg/ml
- Claim 14: a specific concentration set:
- CBD: 25 to 100 mg/ml
- ethanol: 79 mg/ml
- sucralose: 0.5 mg/ml
- strawberry flavoring: 0.2 mg/ml
- sesame oil: q.s. to 1.0 ml
Scope implications
- These dependent claims shift the patent into an “oral solution vehicle” lane. If an accused CBD product differs materially (different oil base, different sweetener, different flavor system, different ethanol level, or different concentration architecture), it can fall outside claims 8–14 even if it satisfies claim 1.
- Concentration ranges are broad (25–100 mg/ml for CBD) but the explicit ethanol/sucralose/flavor numbers in claim 14 can be a strong design-around target if the accused formulation is not tightly matched.
How do you assess likely claim charts for infringement? (Product and protocol elements to map)
A practical infringement claim chart for US 10,111,840 would track four element blocks:
- Indication and seizure type
- “atonic seizures” in Dravet or Lennox-Gastaut
- CBD composition specification
- CBD ≥ 98% (w/w)
- Δ9-THC ≤ 0.15% (w/w)
- Dose
- Adjunct/vehicle (dependent claim escalators)
- adjunct AED combination from enumerated list, plus dose reduction / fewer AEDs
- or the specific oral formulation system (sesame oil/ethanol/sucralose/strawberry) and concentration architecture
What is the US patent landscape around CBD for Dravet and Lennox-Gastaut (and where does 10,111,840 sit)?
Positioning: US 10,111,840 is a regimen-and-specification patent rather than a broad “CBD reduces seizures” patent. In the US CBD epilepsy space, the landscape typically bifurcates into:
- Core product assets: purity/THC control, manufacturing, and/or drug substance specifications
- Method-of-use assets: seizure types, syndrome populations, dose regimens, and combination strategies
- Formulation assets: oral solution vehicle, excipients, concentration, and stability
- Regulatory exclusivity and Orange Book listings: listed patents tied to specific NDA holders and approved strengths/formulations
Because you provided only the claim text and not the patent’s bibliographic data (assignee, priority dates, continuations, or prosecution history), the analysis below focuses on scope and typical competitor mapping rather than asserting exact “expiration dates” or “listed-by Orange Book” status.
Adjacent claim clusters in the CBD epilepsy portfolio (what competitors usually fence)
- Dose regimen specificity (fixed or narrow ranges)
- THC impurity thresholds and “fraction of THC” control
- Adjunct therapy protocols with reduction in benzodiazepine or other AED dosing
- Liquid formulation composition constraints (oil base, ethanol level, sweetener and flavor)
- Seizure phenotype limitations (including “atonic seizures” vs. broader seizure language)
Where 10,111,840 is distinctive
- The combination of:
- “atonic seizures” + Dravet/LGS
- CBD purity ≥ 98% and Δ9-THC ≤ 0.15%
- “about 20 mg/kg/day”
- plus optional vehicle-specific oral solution constraints
…makes it more difficult to design around than generic “CBD for epilepsy” method-of-use claims.
What generic or biosimilar entry risks exist for a CBD product that targets Dravet/LGS?
Risk drivers for would-be entrants
An entrant faces heightened risk if it:
- positions its product for atonic seizures in Dravet/LGS
- uses a CBD material and drug product spec that falls within ≥98% CBD / ≤0.15% Δ9-THC
- uses a dosing regimen near 20 mg/kg/day
- sells an oral solution formulation that matches the excipient/vehicle pattern in claims 8–14
Risk reduction pathways
Lower risk is more likely if the entrant can:
- shift CBD purity/THC spec outside the claim limits (for example, THC above 0.15% w/w or CBD below 98% w/w)
- adopt a dosing regimen that is not “about 20 mg/kg/day”
- avoid the vehicle requirements if those dependent claims are asserted (e.g., different oil and sweetener/flavor systems or materially different ethanol/sucralose/strawberry flavoring levels)
- avoid proving “reduction” elements in dependent claims 6–7, if they are asserted
How does US 10,111,840 compare with typical CBD epilepsy patent families (method vs product vs formulation)?
US 10,111,840 is strongest on method-of-use with fixed quality and dose constraints. Many competitor patents in this space are product-quality, manufacturing, or formulation-focused. In enforcement strategy, litigants often pair:
- a method-of-use claim (treatment regimen and patient phenotype) with
- product/formulation patents (drug substance purity, excipient system, or dosage form matching)
If an accused product differs on formulation but uses the same effective dosing and CBD spec, claim 1 can still be the primary weapon. If CBD spec and dosing match but the formulation differs, the enforcement can instead shift to the method-only portion and keep the formulation dependent claims as fallback.
What patent litigation angles are suggested by this claim set?
Given the claim content, the main litigation angles tend to be:
- Product spec proof
- COAs, batch analytics, impurity profiles, and THC measurement methodology
- Dosing proof
- prescribing protocols, titration schedules, and administered dose records
- Clinical regimen proof for dependent claims
- evidence of concomitant AED dose reductions and AED count reduction “with CBD” compared to “without CBD”
- Formulation proof
- composition composition analysis for sesame oil/ethanol/sucralose/strawberry flavoring and concentration architecture
Key Takeaways
- US 10,111,840 is a narrow, high-specificity method-of-treatment patent for atonic seizures in Dravet or Lennox-Gastaut, using CBD with ≥98% CBD and ≤0.15% Δ9-THC at about 20 mg/kg/day.
- The most enforceable infringement pathway is through claim 1 because it combines indication (atonic seizures + syndromic population) with quality specs and a dose regimen.
- Dependent claims broaden enforcement options through adjunct AED combination from an enumerated list and through treatment de-escalation (reduced AED count and reduced AED dosing), but these can be harder to prove because they require comparative baseline reductions.
- Dependent claims 8–14 add a formulation/vehicle fence: sesame oil as solvent, ethanol as co-solvent, sucralose and strawberry flavor, and specific concentration allocations that can be targeted for design-around.
FAQs
1) Does US 10,111,840 cover any CBD for epilepsy, or only atonic seizures?
It is limited to “atonic seizures” in patients with Dravet syndrome or Lennox-Gastaut syndrome.
2) If a competitor’s CBD product has less than 98% CBD purity, does that avoid claim 1?
Yes in principle: claim 1 requires CBD purity of at least 98% (w/w).
3) If a competitor’s Δ9-THC is 0.2% (w/w) but otherwise matches dosing and indication, does that fall outside the patent?
Yes in principle: claim 1 requires Δ9-THC no more than 0.15% (w/w).
4) Are the excipient details in claims 8–14 required for infringement of claim 1?
No. Claims 8–14 are dependent on claim 1. Claim 1 can be asserted without meeting the specific formulation elements in the dependents.
5) What element is most likely to drive evidentiary fights: dose, purity, or AED reductions?
Purity/THC and dose are typically the cleanest for evidence collection (COAs and dosing records). AED “reduction” claims (6–7) usually require more comparative clinical evidence.
References
- United States Patent No. 10,111,840. Claims 1–14 (provided).
